These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9696068)

  • 21. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
    Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
    J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease.
    Brindle N; Song Y; Rogaeva E; Premkumar S; Levesque G; Yu G; Ikeda M; Nishimura M; Paterson A; Sorbi S; Duara R; Farrer L; St George-Hyslop P
    Hum Mol Genet; 1998 May; 7(5):933-5. PubMed ID: 9536099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
    Combarros O; Riancho JA; Infante J; Sañudo C; Llorca J; Zarrabeitia MT; Berciano J
    Dement Geriatr Cogn Disord; 2005; 20(2-3):153-7. PubMed ID: 16020944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
    Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
    Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.
    Wang Z; Jiang Y; Wang X; Du Y; Xiao D; Deng Y; Wang J
    Med Sci Monit; 2015 May; 21():1408-13. PubMed ID: 25978873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
    Tilley L; Morgan K; Grainger J; Marsters P; Morgan L; Lowe J; Xuereb J; Wischik C; Harrington C; Kalsheker N
    Eur J Hum Genet; 1999 Sep; 7(6):659-63. PubMed ID: 10482954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Butyrylcholinesterase K and apolipoprotein ε4 affect cortical thickness and neuropsychiatric symptoms in Alzheimer's disease.
    Yoo HB; Lee HW; Shin S; Park SW; Choi JS; Jung HY; Cha J; Lee JM; Lee JY
    Curr Alzheimer Res; 2014 Feb; 11(2):137-44. PubMed ID: 24479631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Butyrycholinesterase K variant and Alzheimer's disease.
    Panegyres PK; Mamotte CD; Vasikaran SD; Wilton S; Fabian V; Kakulas BA
    J Neurol; 1999 May; 246(5):369-70. PubMed ID: 10399868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans.
    Kim KW; Jhoo JH; Lee JH; Lee KU; Lee DY; Youn JC; Youn JY; Woo JI
    J Neural Transm (Vienna); 2001; 108(10):1159-66. PubMed ID: 11725818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
    Han HJ; Kwon JC; Kim JE; Kim SG; Park JM; Park KW; Park KC; Park KH; Moon SY; Seo SW; Choi SH; Cho SJ
    Eur Neurol; 2015; 73(1-2):23-8. PubMed ID: 25376930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain).
    Déniz-Naranjo MC; Muñoz-Fernández C; Alemany-Rodríguez MJ; del Carmen Pérez-Vieitez M; Aladro-Benito Y; Irurita-Latasa J; Sánchez-García F
    Neurosci Lett; 2007 Oct; 427(1):34-8. PubMed ID: 17923322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein E phenotypes in healthy normal controls and demented subjects with Alzheimer's disease and vascular dementia in Mie Prefecture of Japan.
    Nakayama S; Kuzuhara S
    Psychiatry Clin Neurosci; 1999 Dec; 53(6):643-8. PubMed ID: 10687744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population.
    Simão-Silva DP; Bertolucci PH; de Labio RW; Payão SL; Furtado-Alle L; Souza RL
    Chem Biol Interact; 2013 Mar; 203(1):358-60. PubMed ID: 23022600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age at onset: an essential variable for the definition of genetic risk factors for sporadic Alzheimer's disease.
    Beyer K; Lao JI; Latorre P; Ariza A
    Ann N Y Acad Sci; 2005 Dec; 1057():260-78. PubMed ID: 16399900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. alpha 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E epsilon 4 allele carriers.
    Yoshiiwa A; Kamino K; Yamamoto H; Kobayashi T; Imagawa M; Nonomura Y; Yoneda H; Sakai T; Nishiwaki Y; Sato N; Rakugi H; Miki T; Ogihara T
    Ann Neurol; 1997 Jul; 42(1):115-7. PubMed ID: 9225693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese.
    Lee DW; Liu HC; Liu TY; Chi CW; Hong CJ
    Am J Med Genet; 2000 Apr; 96(2):167-9. PubMed ID: 10893490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. APOE is associated with age-of-onset, but not cognitive functioning, in late-life depression.
    Butters MA; Sweet RA; Mulsant BH; Ilyas Kamboh M; Pollock BG; Begley AE; Reynolds CF; DeKosky ST
    Int J Geriatr Psychiatry; 2003 Dec; 18(12):1075-81. PubMed ID: 14677138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
    Patterson CE; Todd SA; Passmore AP
    Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved prediction of early-onset coronary artery disease using APOE epsilon4, BChE-K, PPARgamma2 Pro12 and ENOS T-786C in a polygenic model.
    Nassar BA; Rockwood K; Kirkland SA; Ransom TP; Darvesh S; MacPherson K; Johnstone DE; O'Neill BJ; Bata IR; Andreou P; Jeffery JS; Cox JL; Title LM
    Clin Biochem; 2006 Feb; 39(2):109-14. PubMed ID: 16298355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Confirmed Synergy Between the ɛ4 Allele of Apolipoprotein E and the Variant K of Butyrylcholinesterase as a Risk Factor for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Ratis RC; Dacoregio MI; Simão-Silva DP; Mateus RP; Machado LPB; Bonini JS; da Silva WCFN
    J Alzheimers Dis Rep; 2023; 7(1):613-625. PubMed ID: 37483326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.